Anavex Life Sciences Corp (AVXL)

[Steady_T]

That kind of genetic patient selection is a doubled edged sword.

Figure out who the super responders are and select only them for the trial then the label restrictions are narrowed to that population. It does give a high probability of a successful trial.

I'm thinking that by identifying the super responders, the trial population can be selected so that there is a proper representation of them in the trial. That way the results are not skewed either way by an unknown amount of them. The result is still likely to be as positive as the P2a&b trials but without the label restriction narrowing the applicable population.

The certainty level of trial success goes up.